Petaluma biotech company Oculus Innovative Sciences could lose its listing on the Nasdaq exchange after failing to meet the stock market's minimum capital requirement.

Oculus' market value fell below the $35 million benchmark needed for continued Nasdaq listing, the company said in a filing with securities regulators last week.

Oculus is still being listed and traded on the exchange, but it must regain the $35 million minimum market value by Nov. 19 or be subject to delisting.

Oculus shares closed Friday at 74 cents, down a cent from Thursday.

The Petaluma company makes a family of products based on Microcyn, an infection-fighting solution for dermatology, oral care, surgical, wound care, animal health care and other markets. Its products are sold in the U.S., Europe, India, China, Mexico and several Middle East countries.

Oculus went public in 2007 with a $24.2 initial public offering.